Sign Up for a Free Account
  • Updated 05.03.2021
  • Released 09.08.2011
  • Expires For CME 05.03.2024

Immunotherapy in neuromuscular disorders

Introduction

Overview

An increasing number of immunotherapies are being used to treat the heterogeneous group of neuromuscular diseases believed to have an autoimmune pathogenesis. Current treatment options are discussed for the most frequent of these diseases: inflammatory neuropathies, myasthenia gravis, and the inflammatory myopathies. New therapies used in these diseases, including biological agents (monoclonal antibodies or recombinant proteins), are also reviewed.

Key points

• Classic immunosuppressants remain the most beneficial and widely used drugs for immune-mediated neuromuscular diseases.

• Most patients with immune-mediated neuromuscular diseases experience improvement of symptoms and quality-of-life measures with appropriate treatment.

• Several specific therapies have emerged as potential treatments for immune-mediated neuromuscular diseases.

• Subcutaneous immunoglobulin is a less expensive and better tolerated option than intravenous immunoglobulin.

• Biological agents have emerged as effective therapies for patients with treatment-resistant immune-mediated neuromuscular diseases.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com